- Shares of Silverback Therapeutics are up 12% in premarket trading as Regeneron ("REGN") will supply its Libtayo (cemiplimab-rwlc) monoclonal antibody treatment to Silverback ("SBTK") for an evaluation of the latter's SBT6050 in HER-2 expressing non-small cell lung cancer and gastric cancer.
- Silverback will expand a phase 1 trial to evaluate SBT6050, a member of a new class of targeted immuno-oncology therapies, in combination with the PD-1 Libtayo, in dose expansion cohorts.
- Libtayo is currently approved as a first-line NSCLC treatment.